INTEGRA LIFESCIENCES HOLDINGS CORP Form 10-O November 01, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ^x 1934

For the quarterly period ended September 30, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to **COMMISSION FILE NO. 0-26224**

INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) 51-0317849 (I.R.S. EMPLOYER **IDENTIFICATION NO.)**

311 ENTERPRISE DRIVE 08536 PLAINSBORO, NEW JERSEY (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (609) 275-0500

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be

submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer x Accelerated filer 0

Non-accelerated filer o Smaller reporting companyo

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No \acute{y}

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes o No \acute{y}

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 10-Q

The number of shares of the registrant's Common Stock, \$0.01 par value, outstanding as of October 30, 2018 was 85,179,535.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION INDEX

| | Page Number |
|--|----------------|
| PART I. FINANCIAL INFORMATION | |
| Item 1. Financial Statements | <u>3</u> |
| Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2018 and 2017 (Unaudited) | <u>3</u> |
| Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017 (Unaudited) | <u>4</u> |
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017 (Unaudited) | <u>5</u> |
| Notes to Unaudited Condensed Consolidated Financial Statements | <u>8</u> |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>33</u> |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | <u>45</u> |
| Item 4. Controls and Procedures | <u>46</u> |
| PART II. OTHER INFORMATION | |
| Item 1. Legal Proceedings | <u>47</u> |
| Item 1A. Risk Factors | <u>48</u> |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | <u>48</u> |
| Item 4. Mine Safety Disclosures | <u>48</u> |
| Item 5. Other Information | <u>48</u> |
| Item 6. Exhibits | <u>48</u> |
| <u>SIGNATURES</u> | <u>50</u> |
| Exhibit 31.1 Exhibit 31.2 Exhibit 32.1 | |

EX-101 INSTANCE DOCUMENT EX-101 SCHEMA DOCUMENT EX-101 CALCULATION LINKBASE DOCUMENT EX-101 DEFINITION LINKBASE DOCUMENT EX-101 LABELS LINKBASE DOCUMENT EX-101 PRESENTATION LINKBASE DOCUMENT Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (In thousands, except per share amounts)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | | | |
|---------------------|--|-----------|------------------------------------|-----------|--|--|
| | 2018 | 2017 | 2018 | 2017 | | |
| Total revenue, net | \$365,854 | \$278,834 | \$1,089,126 | \$819,634 | | |
| Costs and expenses: | | | | | | |
| Cost of goods sold | 143,245 | 101,757 | 425,032 | | | |